Inozyme Pharma (INZY) Jefferies London Healthcare Conference 2024 summary

Strategic focus and pipeline overview

• Developing enzyme replacement therapy targeting ENPP1 for rare disorders affecting bone and blood vessel health, including ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.

• Pipeline includes Phase III for ENPP1 Deficiency, completed Phase II for ABCC6 Deficiency, and recent data in calciphylaxis.

• Targeting global markets with focus on North America, Brazil, EU, Japan, Middle East, and Turkey, with significant patient prevalence identified.

• Building a rare disease franchise by leveraging experience in patient identification, advocacy, and market development.

Clinical development and regulatory strategy

• Phase I studies completed for all three diseases; pivotal Phase III study (ENERGY 3) in children with ENPP1 Deficiency nearing full enrollment, with readout expected early 2026.

• Regulatory endpoints for ENPP1 Deficiency include raising PPi and showing trends in rickets improvement; U.S. and EU requirements differ slightly in statistical thresholds.

• ABCC6 Deficiency program plans a pivotal pediatric study using major adverse clinical events as endpoints, with regulatory discussions ongoing.

• Calciphylaxis program completed Phase I, showing ability to raise PPi in dialysis patients; pivotal study planned for next year.

Key clinical findings and market insights

• ENPP1 Deficiency studies show favorable safety, effective PPi elevation, and positive trends in bone and patient-reported outcomes.

• ABCC6 Deficiency studies demonstrate clean safety, PPi normalization, and improvements in vascular and visual function.

• Medical record searches and natural history studies reveal significant underdiagnosed pediatric populations, supporting market potential.

• Early prevalence estimates suggest potential for multiple blockbuster therapies in rare disease markets.